Lung disease treatments and earlier screening could help address conditions that progressively restrict breathing and physical activity. United Therapeutics announced new analyses ahead of CHEST 2026 involving pulmonary arterial hypertension and lung scarring. A planned analysis found that ralinepag reduced clinical worsening across groups with different baseline risk indicators. An exploratory analysis found that inhaled treprostinil reduced repeated disease progression events compared with placebo in idiopathic pulmonary fibrosis. Separate observational findings highlighted elevated estimated mortality risk and substantial functional impairment among patients with lung disease. These results support further evaluation of treatment and screening strategies, not changes to medication without specialist advice. The report provides no numerical treatment effects or safety details, and FDA acceptance of the applications does not mean approval for these uses.
